$100.27-0.4%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
Company outlook: revenue of $1.9B to $1.9B for Fiscal year 2026 — up 35.5% on a year earlier
Just reported
From Halozyme Therapeutics, Inc.'s results release of November 5, 2026; its quarterly report has since been filed.
Actual
$493M
+39% y/y
+2.5% q/q
Guided
—
No guide given
Actual
$2.01
+41% y/y
+5.8% q/q
Guided
—
No guide given
EPS, adjusted: $2.39
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $493M | $354.3M | +39.15% |
| Profit | $247M | $175.2M | +40.99% |
| Profit per share | $2.01 | $1.43 | +40.56% |
| Free Cash Flow | $255.2M | $175.6M | +45.37% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Halozyme Therapeutics, Inc. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Halozyme delivered another exceptional quarter, with total revenue increasing 39% and royalty revenue growing 44% year-over-year to record levels,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
The quote and the company description come from Halozyme Therapeutics, Inc.’s Item 2.02 8-K filed November 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Actual
$295M
+35% y/y
+2.5% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.